Microbiology articles within Nature Reviews Cardiology

Featured

  • Research Highlight |

    SARS-CoV-2 infects macrophages, especially lipid-laden foam cells, in coronary atherosclerotic plaques in patients with COVID-19; this infection initiates a strong proatherogenic inflammatory response, which might contribute to the ischaemic cardiovascular complications in these patients.

    • Gregory B. Lim

  • Comment |

    Despite the high consumption of fermented foods and beverages worldwide, their role in a healthy diet is still up for debate. Some fermented beverages have been demonstrated to protect against cardiovascular disease, but many aspects of the effects of fermented foods on cardiovascular health are uncertain. Better-designed studies are warranted.

    • Ramon Estruch
    •  & Rosa M. Lamuela-Raventós

  • Perspective |

    In this Perspectives article, the authors highlight what is known about cardiovascular sequelae in survivors of COVID-19 and discuss important questions that need to be addressed in prospective studies to understand and mitigate these lasting cardiovascular consequences, including in post-acute COVID-19 syndrome.

    • Benjamin A. Satterfield
    • , Deepak L. Bhatt
    •  & Bernard J. Gersh

  • Research Highlight |

    Patients with cardiovascular disease who live with socioeconomic disadvantage face barriers to healthy living. A new study assessing social disadvantage burden reveals that this patient population has poor adherence to COVID-19 risk-mitigation recommendations.

    • Ciarán Martin Fitzpatrick

  • Research Highlight |

    Antihypertensive therapy, particularly with the use of an angiotensin-converting enzyme inhibitor, improves outcomes in patients with hypertension and SARS-CoV-2 infection, who are susceptible to hyperinflammation and severe outcomes with COVID-19.

    • Gregory B. Lim

  • Review Article |

    This Review summarizes the latest evidence indicating that platelet and endothelial dysfunction are essential components of COVID-19 pathology, describes the potential mechanisms underlying the contribution of cardiovascular risk factors to the most severe outcomes in COVID-19, and highlights the roles of coagulopathy, thrombocytopathy and endotheliopathy in COVID-19 pathogenesis.

    • Sean X. Gu
    • , Tarun Tyagi
    •  & John Hwa

  • Review Article |

    In this Review, Tschöpe and colleagues summarize and evaluate the available evidence on the pathogenesis, diagnosis and treatment of myocarditis and inflammatory cardiomyopathy, with special focus on virus-induced and virus-associated myocarditis. The authors also identify knowledge gaps, appraise available experimental models and propose future directions for the field.

    • Carsten Tschöpe
    • , Enrico Ammirati
    •  & Sophie Van Linthout

  • Comment |

    The COVID-19 pandemic has provided the vital stepping stones to improve how clinical trials are conducted. We provide an overview of the major changes to the clinical trial process instigated by the pandemic and suggest ways to make these changes sustainable.

    • Prakriti Gaba
    •  & Deepak L. Bhatt

  • Review Article |

    The presence of cardiovascular comorbidities is linked with worse outcomes in patients with coronavirus disease 2019 (COVID-19), and COVID-19 can induce cardiovascular damage. In this Review, Wu and colleagues summarize the latest mechanistic and clinical studies that contribute to our current understanding of COVID-19-related cardiovascular disease.

    • Masataka Nishiga
    • , Dao Wen Wang
    •  & Joseph C. Wu

  • Research Highlight |

    In patients with COVID-19, myocardial injury is prevalent and is associated with an adverse prognosis and increased mortality, according to two retrospective cohort studies from China and the USA.

    • Gregory B. Lim

  • Research Highlight |

    According to five new studies, therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) is not associated with an increased risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or with an increased risk of severe disease or in-hospital death among patients with COVID-19.

    • Irene Fernández-Ruiz

  • News & Views |

    The gut microbiota has been associated with many different disorders, including cardiovascular diseases. A new study by Jie and colleagues is the first large case–control study to examine directly the enrichment of certain communities of gut bacteria in patients with atherosclerotic cardiovascular disease compared with control individuals.

    • William T. Barrington
    •  & Aldons J. Lusis

  • Review Article |

    The number of patients undergoing implantation of a cardioverter-defibrillator (ICD) is increasing, as the indications for device therapy have broadened. Despite the mortality benefits associated with ICDs, they can also cause substantial complications. Drs. Wazni and Wilkoff explore the issues involved in managing patients with an ICD and discuss approaches for reducing these adverse effects, from prevention of infection, and the choice of lead and implantation technique, to strategies for programming and monitoring the device.

    • Oussama Wazni
    •  & Bruce L. Wilkoff

Browse broader subjects

Browse narrower subjects

Browse Microbiology across other nature.com journals